|
시장보고서
상품코드
2051426
척수성 근위축증 시장 : 유형별, 치료별, 연령층별, 투여 경로별, 유통 채널별, 지역별Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
척수성 근위축증(SMA) 시장은 2026년에 22억 9,550만 달러로 추정되며, 2033년까지 56억 3,890만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 13.7%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 22억 9,550만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 13.70% | 2033년 시장 규모 예측: | 56억 3,890만 달러 |
척수성 근위축증(SMA)은 말초신경계, 중추신경계 및 의지근(골격근)의 운동에 영향을 미치는 유전성 질환입니다. SMA는 주로 근육에 영향을 미치기 때문에 '근육'이라고 불립니다. 신경세포의 자극을 받지 못하는 근육은 위축됩니다. '위축'은 의학용어로 신경세포의 자극을 받지 않는 근육이 줄어드는 것을 말합니다. SMA는 척수에 있는 운동 뉴런이라는 신경세포의 손실을 동반하는 운동 뉴런 질환입니다. 주로 영유아와 소아에게 발병하지만, 성인에게도 발병할 수 있습니다. SMA 환자는 두 개의 결손 또는 변이된 생존운동신경세포1(SMN1) 유전자를 물려받습니다.
시장 역학
시장 내 주요 기업들의 신제품 출시 증가는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 8월, 일본에서 사업을 전개하는 제약회사 중외제약은 척수성 근위축증(SMA) 치료제 '에브리스디 건조시럽 60mg(일반명 : 리스디프람)을 출시했다고 발표했습니다.
또한, 주요 기업들의 제휴 및 공동 연구와 같은 비유기적 전략의 채택이 증가함에 따라 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 3월, 전 세계 SMA 연구의 주요 자금 지원 단체인 척수성 근위축증 재단(Spinal Muscular Atrophy Foundation)과 미국 소재 제약회사 PTC Therapeutics, Inc. SMA 및 기타 신경근육 질환에 대한 과학적 연구를 촉진하기 위해 새로운 치료법 및 재생의료 개발에 초점을 맞춘 새로운 파트너십을 체결했습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 전 세계 척수성 근위축증(SMA) 시장의 주요 기업을 분석합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 세계 척수성 근위축증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 한다1.
- 이해관계자들은 세계 척수성 근위축증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 척수성 근위축증 시장 : 유형별, 2021-2033년
제5장 세계의 척수성 근위축증 시장 : 치료별, 2021-2033년
제6장 세계의 척수성 근위축증 시장 : 연령층별, 2021-2033년
제7장 세계의 척수성 근위축증 시장 : 투여 경로별, 2021-2033년
제8장 세계의 척수성 근위축증 시장 : 유통 채널별, 2021-2033년
제9장 세계의 척수성 근위축증 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 섹션
KSM 26.06.16Spinal Muscular Atrophy Market is estimated to be valued at USD 2,295.5 Mn in 2026 and is expected to reach USD 5,638.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,295.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.70% | 2033 Value Projection: | USD 5,638.9 Mn |
Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.
Market Dynamics
The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2022, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).
Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2022, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market
Market Segmentation
- Global Spinal Muscular Atrophy Market, By Type (Revenue, USD Mn, 2021 - 2033)
- Type I
- Type II
- Type III
- Type IV
- Global Spinal Muscular Atrophy Market, By Treatment (Revenue, USD Mn, 2021 - 2033)
- Gene Therapy
- Disease-modifying drugs
- Global Spinal Muscular Atrophy Market, By Age Group (Revenue, USD Mn, 2021 - 2033)
- Infant
- Adult
- Global Spinal Muscular Atrophy Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Injectables
- Global Spinal Muscular Atrophy Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Spinal Muscular Atrophy Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Biogen, CYTOKINETICS
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- PTC Therapeutics, Inc.
- Novartis AG
- Ionis Pharmaceuticals
- Chugai Pharmaceutical Co., Ltd.
- NMD PHARMA A/S
- Astellas Pharma Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By Age Group
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Acquisitions and Partnerships Scenario
- Technological Advancements
- Regulatory Scenario
- PEST Analysis
- Product Launches
4. Global Spinal Muscular Atrophy Market, By Type, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Type I
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Type II
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Type III
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Type IV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Spinal Muscular Atrophy Market, By Treatment, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Gene Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Disease-modifying drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Spinal Muscular Atrophy Market, By Age Group, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Infant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Adult
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Spinal Muscular Atrophy Market, By Route of Administration, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Injectables
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
8. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
9. Global Spinal Muscular Atrophy Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CYTOKINETICS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PTC Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Chugai Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NMD PHARMA A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
11. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. Section
- References
- Research Methodology
- About Us and Sales Contact
